Performance comparison of three commercial tests for the detection of SARS-CoV-2 antibodies in a common set of pediatric samples
Copyright © 2023 Elsevier B.V. All rights reserved..
BACKGROUND: Serologic testing for SARS CoV-2 is useful for detection of past infection and assisting in diagnosis of post-COVID-19 syndromes such as MIS-C. Immune responses to SARS-CoV-2 infection in children differ from adults but most antibody performance studies are limited to adults.
OBJECTIVE: The objective of this study was to compare three commercial SARS-CoV-2 antibody kits in a common set of children being evaluated for SARS-CoV-2 infection.
METHODS: Three SARS-CoV-2 antibody tests: Abbott anti-nucleocapsid (N) IgG (AA), Epitope Diagnostics anti-N IgG (EDI) and EUROIMMUN anti-S1 Spike IgG (EU) were compared against two references: 1) RT-PCR and 2) consensus IgG (consIgG).
RESULTS: All three tests had a sensitivity <53% compared to RT-PCR, with EU outperforming EDI (p = 0.03). When all samples were compared to consIgG, positive percent agreement was comparable (AA-90%, EU- 98% and EDI- 88%) but EDI had significantly better negative percent agreement than EU (p = 0.009). No difference in test performance was observed using either reference when samples were collected ≥15 days post-symptom onset (PSO).
CONCLUSIONS: Our findings suggest good performance of commercial SARS-CoV-2 IgG assays in pediatric patients with samples collected ≥15 days PSO. Additional studies investigating antibody response and assay performance in children are warranted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:520 |
|---|---|
| Enthalten in: |
Journal of immunological methods - 520(2023) vom: 01. Sept., Seite 113536 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Oyeniran, Sophonie J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 23.08.2023 Date Revised 12.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jim.2023.113536 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360669778 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360669778 | ||
| 003 | DE-627 | ||
| 005 | 20231226083514.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jim.2023.113536 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM360669778 | ||
| 035 | |a (NLM)37567470 | ||
| 035 | |a (PII)S0022-1759(23)00118-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Oyeniran, Sophonie J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Performance comparison of three commercial tests for the detection of SARS-CoV-2 antibodies in a common set of pediatric samples |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.08.2023 | ||
| 500 | |a Date Revised 12.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Serologic testing for SARS CoV-2 is useful for detection of past infection and assisting in diagnosis of post-COVID-19 syndromes such as MIS-C. Immune responses to SARS-CoV-2 infection in children differ from adults but most antibody performance studies are limited to adults | ||
| 520 | |a OBJECTIVE: The objective of this study was to compare three commercial SARS-CoV-2 antibody kits in a common set of children being evaluated for SARS-CoV-2 infection | ||
| 520 | |a METHODS: Three SARS-CoV-2 antibody tests: Abbott anti-nucleocapsid (N) IgG (AA), Epitope Diagnostics anti-N IgG (EDI) and EUROIMMUN anti-S1 Spike IgG (EU) were compared against two references: 1) RT-PCR and 2) consensus IgG (consIgG) | ||
| 520 | |a RESULTS: All three tests had a sensitivity <53% compared to RT-PCR, with EU outperforming EDI (p = 0.03). When all samples were compared to consIgG, positive percent agreement was comparable (AA-90%, EU- 98% and EDI- 88%) but EDI had significantly better negative percent agreement than EU (p = 0.009). No difference in test performance was observed using either reference when samples were collected ≥15 days post-symptom onset (PSO) | ||
| 520 | |a CONCLUSIONS: Our findings suggest good performance of commercial SARS-CoV-2 IgG assays in pediatric patients with samples collected ≥15 days PSO. Additional studies investigating antibody response and assay performance in children are warranted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antibody | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Diagnostic test comparison | |
| 650 | 4 | |a IgG | |
| 650 | 4 | |a Pediatric | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Wang, Huanyu |e verfasserin |4 aut | |
| 700 | 1 | |a Everhart, Kathy |e verfasserin |4 aut | |
| 700 | 1 | |a Mack, Kathy |e verfasserin |4 aut | |
| 700 | 1 | |a Harvey, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Leber, Amy L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of immunological methods |d 1971 |g 520(2023) vom: 01. Sept., Seite 113536 |w (DE-627)NLM000031542 |x 1872-7905 |7 nnns |
| 773 | 1 | 8 | |g volume:520 |g year:2023 |g day:01 |g month:09 |g pages:113536 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jim.2023.113536 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 520 |j 2023 |b 01 |c 09 |h 113536 | ||